Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gufic Biosciences Limited (GUFICBIO.NS)
Mumbai, IN
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.92% | +12.59% | +16.71% | +17.35% | -6.61% | -1.15% | -9.27% | +67.16% | +82.45% | +708.15% | +984.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+15.2% ★ Q1'26: +22.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-8.1% Q1'26: +183.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.5% Q1'26: +17.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.8% Q1'26: +15.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.0% ★ Q1'26: +12.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.67× Q1'26: 2.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
|---|---|---|
| Revenue |
2.40B
est: 2.59B (-7.2%)
|
3.01B
est: 2.92B (+3.0%)
|
| EBITDA |
242.66M
est: 474.76M (-48.9%)
|
435.03M
est: 525.53M (-17.2%)
|
| EBIT |
205.82M
est: 405.17M (-49.2%)
|
386.14M
est: 448.49M (-13.9%)
|
| Net Income |
90.21M
est: 146.30M (-38.3%)
|
164.76M
est: 237.57M (-30.6%)
|
| SGA |
68.07M
est: 392.84M (-82.7%)
|
74.92M
est: 434.85M (-82.8%)
|
| EPS |
1.17
est: 1.46 (-20.0%)
|
2.12
est: 2.41 (-12.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jayesh Pannalal Choksi | Chairman & MD | 9M | male |
| Pranav Jayesh Choksi | Chief Executive Officer & Whole Time Director | 7M | male |
| Devkinandan Roonghta | Chief Financial Officer | 3M | male |
| Pankaj Jayakumar Gandhi | Whole-Time Director | 2M | male |
| Ami Naresh Shah | Senior Manager of Legal, Company Secretary & Compliance Officer | 893.0K | female |
| Sunil Desai | Head Human Resource Department | — | male |
| Ashok Dev | President of Operation | — | male |
| Avik Das | Investor Relations Officer | — | male |
| Nagesh Yarrabathina | Chief Operating Officer | — | male |
| Pinak Padhya | Associate Vice President - Sales & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GUFICBIO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
